Trump’s Next 1,000 Days: Advice For The Pharma C-suite

Although signs suggest the Trump Administration is moving back to the establishment center, biopharma’s knowledge elites remain in the populists’ crosshairs. It’s vital to change the narrative on medicines and markets. In this brief opinion piece In Vivo provides seven ways for the C-suite to do just that.